Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3019% above fair value
$1.34−0.26 (-16.51%)
Close on Nov 12, 2026Market cap $160.56MP/E –Yield –
Fate Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Fate Therapeutics's enterprise value was $33.49M on Nov 11, 2026, against -$83.94M a year earlier. Over the last 5 years it ranged from -$189.05M to $5.45B, with a median of $154.35M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $33.49M | – |
| 2025 | Dec 31, 2025 | -$102.09M | – |
| 2024 | Dec 31, 2024 | -$109.01M | -132.5% |
| 2023 | Dec 29, 2023 | $335.38M | -62.6% |
| 2022 | Dec 30, 2022 | $897.77M | -83.5% |
| 2021 | Dec 31, 2021 | $5.45B | -27.9% |
| 2020 | Dec 31, 2020 | $7.56B | +509.7% |
| 2019 | Dec 31, 2019 | $1.24B | +88.1% |
| 2018 | Dec 31, 2018 | $659.20M | +193.2% |
| 2017 | Dec 29, 2017 | $224.86M | +334.7% |
| 2016 | Dec 30, 2016 | $51.73M | +20.2% |
| 2015 | Dec 31, 2015 | $43.04M | -36.6% |
| 2014 | Dec 31, 2014 | $67.90M | – |
| 2013 | Dec 31, 2013 | -$8.21M | – |
See a number that looks wrong?